Repare Therapeutics (NASDAQ:RPTX - Get Free Report) was upgraded by investment analysts at Bloom Burton from an "accumulate" rating to a "buy" rating in a research note issued on Friday, Zacks.com reports.
Separately, HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Repare Therapeutics in a research report on Wednesday, February 21st.
Get Our Latest Analysis on RPTX
Repare Therapeutics Trading Up 4.3 %
NASDAQ:RPTX traded up $0.13 during trading hours on Friday, reaching $3.15. The company had a trading volume of 219,182 shares, compared to its average volume of 107,343. Repare Therapeutics has a 52 week low of $2.98 and a 52 week high of $13.85. The firm has a market cap of $116.55 million, a price-to-earnings ratio of -1.41 and a beta of 0.56. The firm's 50 day moving average price is $5.30 and its 200-day moving average price is $5.69.
Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last issued its earnings results on Wednesday, February 28th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.11). The firm had revenue of $13.05 million during the quarter, compared to the consensus estimate of $15.92 million. Repare Therapeutics had a negative return on equity of 39.82% and a negative net margin of 183.43%. On average, analysts forecast that Repare Therapeutics will post -2.74 earnings per share for the current fiscal year.
Institutional Trading of Repare Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of RPTX. Deutsche Bank AG acquired a new position in shares of Repare Therapeutics in the 4th quarter worth approximately $40,000. Wells Fargo & Company MN grew its position in shares of Repare Therapeutics by 185.8% in the 4th quarter. Wells Fargo & Company MN now owns 3,041 shares of the company's stock valued at $45,000 after buying an additional 1,977 shares during the last quarter. Barclays PLC purchased a new position in shares of Repare Therapeutics in the 2nd quarter valued at $36,000. UBS Group AG grew its position in shares of Repare Therapeutics by 26.3% in the 3rd quarter. UBS Group AG now owns 3,551 shares of the company's stock valued at $43,000 after buying an additional 739 shares during the last quarter. Finally, SRS Capital Advisors Inc. purchased a new position in shares of Repare Therapeutics in the 1st quarter valued at $49,000. Hedge funds and other institutional investors own 85.09% of the company's stock.
About Repare Therapeutics
(
Get Free Report)
Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.
Featured Articles
Before you consider Repare Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repare Therapeutics wasn't on the list.
While Repare Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
